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mAbs have become an important therapeutic 
strategy in toxin neutralization. A historically 
established role of antibody-mediated immu-
nity includes the ability to interfere with toxins 
by binding and interfering with its interactions 
with host cells. However, despite the fact that 
toxin neutralization was first described in the 
1890s (von Behring and Kitasato, 1991), key ele-
ments of this process remain poorly understood. 
For example, the role, if any, of antibody constant 
regions and Fc receptors (FcRs) on antibody-
mediated toxin neutralization remains largely 
unexplored for most toxin–antitoxin systems.
Understanding the role of FcR is particularly 
important for the currently available anthrax 
vaccine, which is believed to mediate protec-
tion by eliciting antibodies that neutralize the 
protective antigen (PA) component of anthrax 
toxin yet is poorly immunogenic and does not 
protect all hosts against experimental anthrax 
(Wang  and  Roehrl,  2005). The  neutralizing 
antibody response to PA is the best established 
correlate of vaccine-mediated protection against 
anthrax (Little et al., 1997; Reuveny et al., 2001). 
Established mechanisms of antibody-mediated 
neutralization of PA are blocking PA binding 
to its receptor (Little et al., 1997) and slowing 
down the proteolytic digestion of this protein by 
furin (Rivera et al., 2006). Hence, each mecha-
nism is currently thought to depend only on the   
interaction of antibody and toxin. Consistent with 
this notion, several studies have shown that pro-
tection against an anthrax challenge is based on 
antibody-neutralizing toxin components and 
that Fab fragments of antibodies induced by 
vaccination are sufficient for protection (Maynard 
et al., 2002; Wild et al., 2003; Laffly et al., 2005; 
Mabry et al., 2005; Harvill et al., 2008). These 
findings can be interpreted as indicating that   
neither FcR binding nor the Fc domain is essen-
tial for toxin neutralization. However, a role for   
FcR in anthrax toxin neutralization was suggested 
by the recent observations that polyclonal serum 
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One important function of humoral immunity is toxin neutralization. The current view posits 
that neutralization results from antibody-mediated interference with the binding of toxins to 
their targets, a phenomenon viewed as dependent only on antibody specificity. To investigate 
the role of antibody constant region function in toxin neutralization, we generated IgG2a and 
IgG2b variants of the Bacillus anthracis protective antigen–binding IgG1 monoclonal antibody 
(mAb) 19D9. These antibodies express identical variable regions and display the same speci-
ficity. The efficacy of antibody-mediated neutralization was IgG2a > IgG2b > IgG1, and 
neutralization activity required competent Fc receptor (FcR). The IgG2a mAb prevented 
lethal toxin cell killing and mitogen-activated protein kinase/extracellular signal-regulated 
kinase kinase cleavage more efficiently than the IgG1 mAb. Passive immunization with IgG1 
and IgG2a mAb protected wild-type mice, but not FcR-deficient mice, against B. anthracis 
infection. These results establish that constant region isotype influences toxin neutralization 
efficacy of certain antibodies through a mechanism that requires engagement of FcR. These 
findings highlight a new parameter for evaluating vaccine responses and the possibility of 
harnessing optimal FcR interactions in the design of passive immunization strategies.
© 2010 Abboud et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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trace of IgG1. DNA sequence analysis confirmed that the heavy 
and light chain variable VH7183 and VKBD2 regions of mAbs 
19D9 IgG1, IgG2a, and IgG2b were identical.
Given that isotype can affect fine specificity (Torres and 
Casadevall, 2008), the IgG2a and IgG2b switch variants were 
compared with the parent 19D9 IgG1 for their antigen binding 
characteristics. The observed IgG1, IgG2a, and IgG2b binding 
to PA was the same (Fig. 1 A), and IgG1 binding was inhibited 
similarly by the addition of IgG2a or IgG2b (Fig. 1 B). Further-
more, reactivity of the three IgG subclasses with a panel of mu-
tated peptide mimetics that represented the epitope revealed 
similar binding (unpublished data). To further highlight that 
the constant regions did not affect fine specificity of the anti-
bodies, we performed plasmon resonance analysis of IgG sub-
class binding to PA, which revealed that the dissociation 
constants (Kds) of IgG1, IgG2a, and IgG2b were 0.109, 0.149, 
and 0.108 µM, respectively, using the Langmuir fitting model 
to analyze the data. Similar results were obtained if the plasmon 
resonance data were analyzed by the two-state reaction-fitting 
model. These Kd values are essentially identical and were con-
sidered to be within the experimental error of the method.
Protective efficacy of 19D9 IgG1, IgG2a, and IgG2b mAbs 
on LeTx-mediated macrophage cytotoxicity
The cellular intoxication process is initiated by PA binding   
to cell surface receptors known as TEM8 (tumor endothelial 
marker 8; Bradley et al., 2001) and CMG2 (human capillary 
was more effective in the presence of competent receptor 
function (Verma et al., 2009) and that a neutralizing mAb 
lost efficacy in hosts with blocked FcRs (Vitale et al., 2006).   
In contrast, a subset of mAbs to anthrax toxin was suggested to 
potentiate toxin activity through their interaction with FcRs 
(Mohamed et al., 2004). These observations hint at a complex 
role for FcR in antibody-mediated toxin neutralization.
Four different classes of FcRs for IgG have been defined 
on murine and human immune effector cells, including the 
high-affinity FcRI and the low-affinity FcRII and FcRIII 
(for review see Nimmerjahn and Ravetch, 2006). In mice, 
these receptors are categorized into two groups: the activating 
receptors FcRI, FcRIII, and FcRIV and the inhibitory 
receptor FcRIIB. Antibody-antigen binding events lead to 
effector functions that mediate antibody-dependent cytotox-
icity or complement activation by FcR engagement on mac-
rophages, dendritic cells, natural killer cells, neutrophils, and 
other cell types. Receptor assembly and signal transduction for 
all activating FcRs in mice is mediated by the  chain (Ra   
et al., 1989; Kurosaki et al., 1991). Deletion of the  chain leads 
to loss of the ability to phagocytose antibody-coated particles, 
despite retaining the ability to bind (Takai et al., 1994).
In this paper, we report that IgG1, IgG2a, and IgG2b mAbs 
derived from one B cell precursor, sharing identical variable   
regions, differ in toxin neutralization capacity. In addition, none 
of the IgG subclasses was effective in altering lethal toxin 
(LeTx)  cytotoxicity  in  FcR/  and  FcR  chain/FcRII 
double  knockout  (FcR//RIIB/)  BM-derived  macro-
phages (BMMs) and in Bacillus anthracis infection in mice, 
suggesting that, for this mAb set, protection is modulated by 
Fc-dependent functions. These results imply that antibody iso-
type is an important variable in toxin neutralization through 
effects mediated by Fc domain interactions with FcR.
RESULTS
Generation of IgG2a and IgG2b switch variants
The 19D9 hybridoma makes a PA-neutralizing IgG1 antibody. 
We used the ELISA spot assay to detect spontaneously arising 
variant cells producing new downstream isotypes of IgG1.   
Hybridoma 19D9 spawned IgG2a- and IgG2b-producing cells 
at rates of 105 and 4 × 105, respectively, which is a typical 
isotype switching rate for a hybridoma (Spira and Scharff, 1992; 
Spira et al., 1994). We then attempted to enrich switch variant–
producing cells by sib selection (Spira et al., 1984; Spira and 
Scharff, 1992). Despite successive rounds of enrichment and 
increased switching frequency rates, the variants remained too 
rare to recover. Consequently, we used FACS in combination 
with immunofluorescence staining for surface-associated anti-
body to identify a cell fraction significantly enriched in isotype 
variant cells. Viable cells staining for surface-associated IgG2a or 
IgG2b were isolated by cell sorting on the basis of surface fluor-
escence intensity, a step which enriched the fraction of hybrid-
omas producing variant cells and reduced the fraction of IgG1 
producers. Two rounds of soft agar cloning further stabilized 
the isotype variant cells. Analysis of the supernatants of the 
19D9-derived IgG2a- and IgG2b-secreting clones revealed no 
Figure 1.  Specific and competitive binding of IgG1, IgG2a, and 
IgG2b mAbs to PA. (A) IgG1, IgG2a, and IgG2b mAbs were added at dif-
ferent concentrations to PA bound to polystyrene plates. Binding was 
measured by ELISA. (B) A constant amount of IgG1 (2 µg/ml) and increas-
ing concentrations of IgG2a and IgG2b were allowed to compete for 
binding to PA bound to polystyrene plates. Data shown are representative 
of three independent experiments.JEM VOL. 207, October 25, 2010 
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results  (Muehlbauer  et  al.,  2007),  C57BL/6-derived  BMMs 
were killed within 72 h of LeTx treatment (unpublished data). 
Next,  we  tested  LeTx  susceptibility  of  C57BL/6-derived 
BMMs in the presence of mAb. Consistent with our data, IgG2a 
mAb exhibited increased neutralization activity as compared 
with IgG1 and IgG2b mAbs (P < 0.01; Fig. 3 A). Our findings 
indicate  that  antibody-mediated  protection  against  anthrax 
toxin is dependent on the isotype of the antibody.
To determine whether FcRs played a role in anti-
body-mediated LeTx neutralization, we compared the ability   
of antibody to protect BMMs derived from FcR/ and 
morphogenesis protein 2; Scobie et al., 2003). After cleavage 
at its N-terminal domain by a furin-like protease and hep-
tamerization, the heptamer–receptor complex then acts as a 
docking  platform  that  subsequently  translocates  the  enzy-
matic components LF and EF into the cytosol via acidified 
endosomes (Gordon et al., 1988; Abrami et al., 2003, 2004). 
LF is a zinc metalloprotease that has a very specific and lim-
ited set of substrates (Klimpel et al., 1994) and specifically 
cleaves the N terminal of mitogen-activated protein kinase 
kinases (MAPKKs) or ERK (extracellular signal-regulated   
kinase; Duesbery et al., 1998; Vitale et al., 1998). Although the   
anthrax toxin receptors are present in high concentrations on 
numerous cell types, macrophages are considered key cells in 
the toxin pathogenic effects because macrophage depletion 
can protect mice against toxin infusion (Welkos et al., 1986). 
Consequently, we focused on macrophages when evaluating 
the cytotoxic effects of LeTx and the efficacy of antibody-
mediated protection. As reported previously (Abboud et al., 
2009),  the  19D9  IgG1  mAb  protected  macrophages  from 
LeTx-mediated cytotoxicity. However, when the activity of 
19D9 IgG2a and 19D9 IgG2b was compared with the parent 
IgG1, it was apparent that isotype switching had generated 
more effective neutralizing antibodies such that their relative 
efficacy was IgG2a > IgG2b > IgG1 (Fig. 2 A). To examine 
the concentration-dependent effects of LeTx in the presence 
of a constant amount of mAb (10 µg/ml), RAW 264.7 mac-
rophages were treated with varying concentrations of LF and 
PA as indicated (Fig. 2, B and C). In the presence of a constant 
PA concentration (100 ng/ml), the IgG1 mAb half-maximal 
blockade of cell death was observed at a LF concentration of 
6.25 ng/ml, whereas in the presence of nonlimiting concen-
trations of LF the half-maximal blockade of cell death was 
measured at a PA concentration of 25 ng/ml. Overall, RAW 
264.7 macrophages were protected against LeTx in the pres-
ence of IgG2a mAb. The latter was able to protect cells at all 
concentrations of PA and LF, further distinguishing the en-
hanced efficacy of this isotype relative to IgG1.
Protective efficacy of 19D9 IgG1, IgG2a, and IgG2b mAbs 
requires FcRs
The observations on antibody-mediated LeTx neutralization 
made with RAW 264.7 macrophage-like cells were repeated 
with macrophages from C57BL/6 mice to ascertain their rele-
vance with primary cells. Furthermore, we used additional   
measures of toxicity by analyzing MAPKK cleavage, which is 
performed by LF once it is internalized with the result that 
three MPKK signaling pathways are disrupted (Duesbery et al., 
1998; Chopra et al., 2003). LeTx uptake and subsequent 
MAPKK cleavage also occur in cells that are resistant to LeTx 
killing (Duesbery et al., 1998; Schaeffer and Weber, 1999), sug-
gesting that cells differ in their response to MAPKK cleavage 
(Moayeri et al., 2004; Bonuccelli et al., 2005). To determine 
whether BMMs from C57BL/6 mice were killed by LeTx, 
these cells were treated with or without LeTx (100 ng/ml PA 
and 100 ng/ml LF) and analyzed for cell viability at various 
time intervals after LeTx exposure. Consistent with previous 
Figure 2.  LeTx-neutralizing activity of IgG subclasses on 
RAW264.7 macrophages. Cells were treated with or without LeTx  
(100 ng/ml PA and 100 ng/ml LF) in the presence or absence of varying 
amounts of mAb (A), or treated with or without 10 µg/ml mAb in the 
presence or absence of varying amounts of LF (PA at fixed saturating 
concentrations, 100 ng/ml; B) or PA (LF at fixed saturating concentrations, 
100 ng/ml; C). Viability was established by MTT assay 4 h after LT treat-
ment. Cells treated with IgG2a and IgG2b mAbs showed statistically  
significant elevation in protection with cells treated with IgG1 mAb.  
Significance was determined by Student’s t test. Data shown are repre-
sentative of three independent experiments. Means and standard devia-
tions of triplicates are shown from one representative experiment out  
of three (A).2398 FcR needed for mAb-mediated toxin neutralization | Abboud et al.
it is possible to compete IgG immune complexes with sufficient 
soluble IgG, where this inhibitory capacity is a function of the 
relative affinities of soluble IgG and the IgG immune complex 
for the FcR as well as of the concentrations of both ligands 
(Furriel et al., 1992). As expected, macrophages were not pro-
tected when all three activating FcRs were blocked. Similarly, 
simultaneous blockade of both FcRI and FcRIV and FcRIII 
and FcRIV substantially decreased the protective activity   
of IgG2a (Fig. 3 D). Monolayers treated with only the mAb to 
FcRIV rendered the cells less susceptible to LeTx cytotoxicity, 
suggesting that the IgG2a–PA complex was taken up via FcRI 
or FcRIII. The expression pattern of all four FcRs was   
FcR//RIIB/ mice. None of the mAbs protected mac-
rophages deficient in FcR from LeTx-mediated cytotoxicity 
(Fig. 3 B). The same result was obtained when wild-type 
C57BL/6-derived BMMs were pretreated with mAb 2.4G2 that 
blocks FcRII/III (Fig. 3 C). To further establish that the IgGs 
mediate their effector activities in vitro through their engage-
ment of FcRs and to determine the relative contributions of 
these FcRs to toxin neutralization, we treated RAW macro-
phages with a blocking mAb (9E9) to FcRIV alone and in 
combination with a blocking mAb to FcRIIIs or soluble IgG2a 
(used as a competitor inhibitor to block FcRI) and measured 
the effect of 19D9 IgG2a effect on LeTx toxicity. We note that   
Figure 3.  LeTx-neutralizing activity of IgG1, IgG2a, and IgG2b mAbs is dependent on FcR interactions. (A and B) BMMs from C57BL/6 (A) and 
FcR//RIIB/ (B) mice were plated in 96-well plates at a density of 8 × 104 cells per well in maintenance medium supplemented with FCS, 2 h before 
treatment with LeTx (100 ng/ml PA and 100 ng/ml LF). The indicated concentrations of mAb were added at the same time with LeTx. After 72 h, cell death 
was assayed with MTT (3,(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide; controls were cells treated with LeTx only or with media alone). 
Representative data are shown from three independent experiments. Significance was determined by a Student’s t test. (C) BMMs from C57BL/6 mice 
were plated as described in A and B, and the indicated dilutions of each mAb were used to neutralize LeTx in the presence of anti-FcRII/III (mAb 2.4G2). 
(D) RAW264.7 macrophages were treated with toxin, as described in A and B, and 10 µg/ml IgG2a mAb in the presence of blocking mAb to FcRIII (2.4G2), 
FcRIV (9E9), and/or a competitor inhibitor to block FcRI (IgG2a Std.). (E) RAW264.7 macrophages were gated and analyzed by flow cytometric analysis 
for FcRI, FcRII, FcRIII, and FcRIV expression with specific antibodies. Histograms shaded in gray represent the specific FcR, and histograms shaded 
in black indicates unstained cells used as a control. (F and G) C57BL/6 and FcR//RIIB/ were treated with 100 ng/ml LeTx and 10 µg/ml mAb. MEK-3 
cleavage was determined by Western blotting with anti–MEK-3. Data shown are representative of three independent experiments. Means and standard 
deviations of triplicates are shown from one representative experiment out of three (A and D).JEM VOL. 207, October 25, 2010 
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IgG2a isotype in protecting against B. anthracis on wild-type 
FcR//RIIB/ mice and FcR/ mice infected with 
B. anthracis Sterne. Consistent with the in vitro results, the 
administration of both IgG1 and IgG2a reduced mortality in 
wild-type mice, with IgG2a being the more potent of the 
two, but neither reduced mortality in FcR//RIIB/ or 
FcR/ mice (P < 0.001; Fig. 4).
Uptake of IgG2a-PA by BMMs
We examined the uptake of PA bound to IgG2a by BMMS 
from wild-type and FcR//RIIB/ mice using fluores-
cent microscopy. Cells were cooled to 4°C and labeled with 
low concentrations of IgG2a and PA. Cells were washed to 
remove unbound IgG2a-PA. Internalization was then initi-
ated by incubation at 37°C for varying time intervals and the 
cells were then fixed. PA colocalized with IgG2a in wild-
type BMMs (Fig. 5, D–F). IgG2a-PA were initially located 
on the cell surface and, with time, there was an increase in 
the amount of IgG2a-PA found in the cell interior such that 
the  majority  was  intracellular  after  15  min.  As  expected, 
BMMs lacking FcRs were unable to efficiently internalize 
IgG2a bound to PA. In these mice, there was very little colocal-
ization of IgG2a with PA, which is most likely a result of PA 
binding and entering through its receptors TEM8 or CMG2 
(Fig. 5, J–L).
Interfering with actin and preventing phagocytosis does not 
eliminate antibody-mediated protection
Cross-linking of FcRs by multivalent ligands can initiate both 
phagocytosis and endocytosis; therefore, we sought to define if 
a phagocytic event was involved when these receptors are cross-
linked by IgG-PA. Hence, we tested whether cells treated with 
cytochalasin d (concentrations from 2 to 10 µM), a classical   
inhibitor of phagocytosis by inhibiting actin polymerization, 
could prevent the uptake of antibody-PA, as measured by cell 
viability with the MTT assay. Blocking phagocytosis did not 
interfere with the uptake of antibody and PA, as the protective 
efficacy of both mAbs tested was un-
altered (Fig. 6 A). To examine whether 
FcR activation was sufficient for pro-
tection, we evaluated the toxicity of 
determined and FcRI, FcRII, FcRIII, and FcRIV ex-
pression was detected on RAW macrophages (Fig. 3 E).
To determine whether mAb interfered with the uptake or 
proteolytic activity of LF, we treated C57BL/6 and FcR//
RIIB/ macrophages with LeTx and analyzed the amount of 
MAPK/ERK kinase (MEK)3 found in lysates of cells after vari-
ous treatments by immunoblot (Fig. 3 G). The two groups were 
normalized based on the media-only condition, and Fig. 3 F  
illustrates that toxin leads to a 99 and 78% decrease of MEK-3 
expression in wild-type and FcR//RIIB/, respectively. 
In addition, mAb 19D9 IgG1 was less able to indirectly inhibit 
the LF-mediated rapid cleavage and degradation of MEK-3 in 
C57BL/6 cells than the IgG2a mAb (1–2 h), as demonstrated 
by the loss of uncleaved proteins and more cleaved MEK-3. 
In wild-type macrophages, IgG2a rescued 67% of the protein 
expression and was 10-fold more effective than that in IgG1. 
As measured by the MTT assay (Fig. 4 A), the decrease in cell 
death coincided with the decrease in MEK cleavage by IgG2a. 
Collectively, our findings confirm that IgG2a is more effec-
tive at toxin neutralization relative to IgG1 using MEK cleav-
age as the readout for protection.
In FcR//RIIB/, IgG1 and IgG2a rescued 22.7 and 
33.2% of the MEK-3 expression, respectively, whereas IgG2a 
was 1.5-fold more effective than IgG1. MEK-3 cleavage was 
evident within 1 h of treatment with LeTx, illustrating that 
mAb failed to inhibit the internalization of the PA–LF toxin 
complex and ultimate LF-mediated proteolytic inactivation of 
MAPKKs. These results were consistent with the MTT results 
and show that activating FcRs play a critical and necessary 
role in antibody-mediated toxin neutralization, such that neu-
tralization requires both mAb binding to the toxin and activa-
tion of macrophages through engagement of the FcRs.
Protective efficacy of 19D9 IgG1 and IgG2a mAbs  
on infected FcRg//RIIB/ mice
To ascertain whether the in vitro observations translated into 
in vivo effects, we evaluated the efficacy of the IgG1 and 
Figure 4.  IgG1 and IgG2a mAbs protect 
wild-type but not FcR//RIIB/ or 
FcR/ mice from B. anthracis infection. 
(A) Kaplan-Meier analysis of survival rate of 
FcR//RIIB/ or wild-type mice treated 
with IgG1 and IgG2a mAbs or isotype control 
antibodies (n = 10). (B) Kaplan-Meier analysis 
of survival rate of FcR/ or wild-type mice 
treated with IgG1 and IgG2a mAbs or isotype 
control antibodies (n = 10). The log-rank test 
was used to determine significance between 
wild-type and FcR//RIIB/ and FcR/ 
mouse groups treated with IgG1 and IgG2a 
mAbs. Data shown are representative of two 
independent experiments.2400 FcR needed for mAb-mediated toxin neutralization | Abboud et al.
more effective at reducing LeTx cytotoxic effects 
than the parent IgG1 mAb. This result revealed 
that isotype was pertinent for protecting against 
toxin and that the efficacy of a mAb can be en-
hanced by changing its constant region. For this 
antibody set, the V region amino sequences were 
identical and their serological behavior for pep-
tides  containing  the  epitope  and  for  PA  in   
plasmon resonance analysis was essentially indis-
tinguishable, indicating conservation of fine speci-
ficity and affinity with isotype change. Hence, the 
V region identical set of isotype-switched variants 
behaves differently than two other mAbs where 
isotype change affects specificity (Torres and   
Casadevall, 2008) and suggests that this phenome-
non is probably associated with only certain V re-
gion combinations. Consequently, we can ascribe 
differences in this antibody set to differences in 
the Fc region and its interaction with FcR.
Antibody responses to PA in the mouse are 
predominantly IgG1. Thus, the predominant natural isotype re-
sponse to PA is not the most effective toxin neutralizing isotype. 
The major FcRs engaged by IgG1, IgG2a, and IgG2b on mac-
rophages are different, suggesting at least one explanation for the 
differences in efficacy observed for the three isotypes. The de-
tails of these interactions have been extensively studied in the 
murine system (for review see Nimmerjahn and Ravetch, 2006). 
The high-affinity FcRI exclusively binds IgG2a and the low-
affinity FcRIII binds IgG1, IgG2a, and IG2b (Ravetch and 
Kinet, 1991; Hulett et al., 1994). FcRIV binds IgG2a and 
IgG2b with intermediate affinity but does not interact with 
IgG1 or IgG3 antibody isotypes (Nimmerjahn et al., 2005). Our 
results imply that FcRI, FcRIII, and FcRIV can each play a 
role in FcR-dependent neutralization. Furthermore, our data 
does exclude the possibility that FcRIIB can contribute to this 
neutralization. It is noteworthy that for viral infections the IgG2a 
subclass plays a dominant role in antibody-mediated protection 
(Baldridge and Buchmeier, 1992; Markine-Goriaynoff et al., 
2002). In this paper, we also illustrate that the IgG2a subclass is 
prominent in enhanced protection to experimental anthrax.
The  observation  that  mAb  failed  to  protect  FcR/  
and FcR//RIIB/ mice from B. anthracis challenge while   
protecting mice with competent FcRs demonstrates that 
the FcR chain is essential for antibody-mediated protection. 
The fact that IgG2a mAb was able to protect wild-type mice 
LeTx for RAW 264.7 cells placed on plates coated with a 
control irrelevant IgG1. Stimulation of FcR alone was 
not sufficient to protect the cells from LeTx but did reduce 
their  susceptibility  when  PA-neutralizing  antibody  was 
added, suggesting that prestimulation of FcR enhanced 
antibody-mediated protection (Fig. 6 B). This data suggests that 
the mechanism by which FcRs mediate protection involves a 
signaling pathway that activates these receptors and that the dif-
ferences in efficacy between IgG1 and IgG2a strongly reflect a 
quantitative difference because IgG2a binds to a higher affinity 
receptor and can result in a greater Fc-mediated signal.
DISCUSSION
The importance of antibody isotype in antibody-mediated toxin 
neutralization has not been explored. Perhaps this is not surpris-
ing because many Fab fragments have been shown to neutralize 
toxins. However, the interaction of FcRs with the antibody Fc 
fragment results in a variety of cellular functions depending on 
the cell in which they are expressed. Therefore, both the FcR 
type engaged and the antibody isotype can affect the responses 
of effector cells (Wirthmueller et al., 1992; Ravetch, 1997). Gen-
erating the IgG2a and IgG2b isotype switch variants of an IgG1 
anti-PA mAb showed isotype differences in the ability of the 
mAbs to protect murine macrophages from LeTx-mediated   
cytotoxicity. The IgG2a and IgG2b mAbs were significantly 
Figure 5.  Colocalization between IgG2a mAb and PA.  
Wild-type and FcR//RIIB/ BMMs were cooled to 
4°C, incubated with Alexa Fluor 488–conjugated IgG2a 
(red) and Alexa Fluor 568–conjugated PA (green), washed, 
and warmed to 37°C for the indicated time points. The 
cells were then fixed and analyzed by fluorescence mi-
croscopy. Images in A–C were acquired in a bright field 
and correspond to D–F, respectively, whereas G–I corre-
spond to J–L, respectively. Data shown are representative 
of three independent experiments. Bars, 10 µm.JEM VOL. 207, October 25, 2010 
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of large opsonized particles occurs via phagocytosis (Mellman   
et al., 1984; Aderem and Underhill, 1999). The molecular 
mechanisms underlying FcR-mediated phagocytosis and en-
docytosis differ markedly. Endocytosis requires assembly of 
clathrin at the site of receptor clustering, yet phagocytosis in-
volves formation of an actin phagocytic cup and is blocked by 
inhibitors such as cytochalasin d (Koval et al., 1998). In our ex-
periments, inhibition of actin polymerization by cytochalasin d 
did not interfere with the protective activity of IgG mAbs,   
suggesting that the IgG–PA complex was taken up via FcR- 
mediated endocytosis. However, the prestimulation of FcR 
significantly enhanced antibody-mediated protection of cells. 
Although the mechanism for this effect was not studied in 
detail, possible explanations include up-regulation of FcR to the 
cell surface, which consequently contributed to the antibody- 
dependent clearance of toxin. Alternatively, FcR engagement 
with consequent signal transduction activation could alter the 
metabolism of the macrophage-like cell to reduce its susceptibil-
ity to LeTx. Although we could not prove a role for clathrin in 
the internalization of IgG2a–PA complexes because inhibiting 
assembly of clathrin would also interfere with toxin entry that 
occurs via a clathrin-dependent pathway, it is nevertheless likely 
that clathrin-mediated endocytosis is responsible for internaliz-
ing the bound complexes. Confocal microscopy revealed that 
cross-linking of surface-bound IgG2a–PA caused relocation of 
the receptor–ligand complex to an intracytoplasmic compart-
ment within wild-type cells, with essentially completed internal-
ization occurring within 15 min. We have also shown that this 
redistribution is affected in cells deficient in FcR, revealing   
that it is necessary for FcR to bind and mediate endocytosis   
of IgG2a–PA complex.
The results of this study established that protective anti-
toxin antibodies can be made more protective by switching 
their constant regions to other isotypes and that toxin neu-
tralization is FcR dependent, at least for a subset to toxin-
binding antibodies which includes those used in this study. 
These  observations  establish  an  important  precedent  be-
cause they suggest new options and complexity for anti-
body-mediated  neutralization.  For  example,  our  results 
suggest that there may be optimal combinations of antibody 
specificity, constant region usage, and FcR type that would 
differ depending on the particular antibody and toxin pair. 
Nevertheless,  important  questions  remain  regarding  the 
precise mechanism for toxin neutralization after FcR en-
gagement. In this regard, we hypothesize that mAb binding 
to PA and FcRs may result in an immune complex that is 
endocytosed and sorted to lysosomes for degradation. The 
inability to clear toxin infection in mice deficient in FcRs 
may reflect defective endocytosis and/or loss in functional 
effects on signal transduction pathways mediated by activat-
ing FcRs. The differences in efficacy between IgG1, IgG2a, 
and IgG2b strongly suggest a difference in Fc-mediated ef-
fector functions. Consequently, isotype selection and re-
sponse are important considerations when designing passive 
antibody therapies and evaluating the response to toxin-
neutralizing vaccines.
and not mice deficient in FcRs illustrates that binding to PA 
is a necessary, but not sufficient, condition for complete pro-
tection. Western blot results showed that the mAbs indeed 
prevented LF-mediated MEK-3 cleavage in wild-type cells, 
yet the opposite was observed in the FcR//RIIB/ cells, 
which  in  turn  illustrates  that  without  FcR  engagement, 
mAbs are not able to decrease the LeTx-mediated cytotox-
icity. Thus, the interaction of the Fc portion of the mAb with 
FcR reduced LeTx cytotoxicity by eliminating PA on the 
cell surface, thereby decreasing the PA bound to the cell and 
the LF internalized into the cell cytosol.
Upon engagement of FcRs, the mode of internalization of 
immune complexes is determined by the size of the bound com-
plexes (Daëron, 1997). Small immune complexes are internal-
ized by receptor-mediated endocytosis, whereas internalization 
Figure 6.  Inhibition of phagocytosis by cytochalasin d and up- 
regulation of FcRs by IgG1 control antibody on RAW264.7 macro-
phages. (A) RAW264.7 macrophages that were treated with LeTx and mAb 
or LeTx, mAb, and 2 µM cytochalasin d (Cyto D). Cells were preincubated 
for 45 min with cytochalasin d. Cell viability was determined as indicated 
in the Cell viability assays section of Materials and methods. (B) RAW264.7 
macrophages were either not preincubated or preincubated overnight with 
an IgG1 control antibody (used to preactivate FcRs) and next-day treated 
with toxin and mAb. Data shown are representative of two independent 
experiments. Means and standard deviations of triplicates are shown from 
one representative experiment out of two (A).2402 FcR needed for mAb-mediated toxin neutralization | Abboud et al.
Plates were washed and rinsed with distilled H2O. The spots were counted 
with a dissecting microscope and the median frequencies of switching   
were calculated.
Cells for analysis or selection were centrifuged and washed once with 
FACS buffer supplemented with 1× PBS, 1% FCS, and 1 mM EDTA in sterile 
water. Cells were resuspended at 2.5 × 107 cells/200 µl. Isotype-specific FITC-
conjugated goat anti–mouse antibody was added and allowed to react for   
30 min at 4°C. Cells were resuspended at 5 × 107cells/ml for analysis and sorting. 
Fluorescence cell sorting was performed using a FACSAria (BD) equipped 
with four lasers and coherent sapphire with a 100-mm quartz nozzle. FITC-
labeled detection reagents were excited by the 488-nm spectral line of a   
100-mW diode-pumped solid-state laser. FITC-positive cells were collected 
using a 525-nm band pass filter. For acquisition and statistical analysis, 6.1.1 
Diva software (BD) was used. Live cells were gated using the forward and side 
scatter parameters. Background fluorescence was determined using unlabeled 
cells as a control. Cells sorted for bulk enrichment were collected directly into 
a 12 × 75 mm Falcon tube (BD) containing 1 ml of culture medium supple-
mented with 20% FCS. Cells were centrifuged and resuspended in 1 ml of 
culture medium and then grown in a single well of a 24-well plate.
Cell subcloning was performed using soft agar–containing 0.3–0.4% 
SeaPlaque agarose (FMC Bioproducts). First, 4 ml IMDM cloning medium 
(IMDM with 20% FCS) containing 0.4% SeaPlaque agarose was introduced 
into a 60-mm culture plate (BD). After solidification at 4°C for 10 min, 1 ml 
of the same medium containing 1,000 cells was laid over the top of the soft 
agar and put at 4°C for 10 min. Cells were grown at 37°C for 5–7 d. Clones 
were randomly picked and placed into a 96-well plate.
RNA and RT-PCR. Cells (5–10 × 106) were lysed with 1 ml Trizol 
reagent (Invitrogen) and RNA extracted according to the manufacturer’s 
instructions. About 1 µg of total RNA was reverse transcribed in a 20-µl 
reaction using the Superscript II kit (Invitrogen). Universal 5 (sense) vari-
able region and specific 3 (antisense) constant region primers were used in 
a PCR reaction to generate cDNA encoding the variable domains of mAbs. 
The  primers  are  as  follows:  3MsC,  5-AGACCTATGGGGCTGTT-
GTTTTGGC-3; 3MsCµ, 5-GACATTTGGGAAGGACTGACTCTC-3; 
3MsC,  5-TGGATACAGTTGGTGCAGCATCAGC-3;  5VHuni,   
5-TGAGGTGCAGCTGGAGGAGTC-3; and 5Vuni, 5-GACATTC-
TGATGACCCAGTCT-3. PCR products were cloned and the heavy and 
light chain of the 19D9 IgG2a and IgG2b switch variants were sequenced to 
confirm that they were identical to those of the parent IgG1.
Peptide synthesis. To map the functional linear epitopes of PA, biotinyl-
ated soluble peptides representing the entire length of PA were synthesized 
as 15-mers, overlapping by 10 residues (total of 145 peptides) according to 
guidelines of the manufacturer (Invitrogen). Biotinylation of the peptides 
was performed by coupling d-biotine to the N terminus. The identity of 
each of the peptides was confirmed by mass spectral analysis. The peptides 
were >98% pure, as assessed by high-pressure liquid chromatography analy-
sis, and peptides were supplied as a white powder soluble in water. All pep-
tides were stored at a concentration of 1 mg/ml.
ELISAs for PA and peptides. Antibody binding to PA and PA-derived 
peptides was studied by ELISAs. In brief, the wells in polystyrene plates (Costar) 
were coated overnight with 1 µg/ml of recombinant PA in PBS. The plates 
were then blocked with 2% BSA/PBS and incubated for 1 h at 37°C. After the 
wells were washed with 0.1% Tween 20 in PBS (PBST), serial dilutions of pu-
rified MAbs were added and incubated at 37°C for 1 h. After washing, bound 
antibodies were detected with isotype-specific alkaline phosphatase–conjugated 
goat anti–mouse reagent (SouthernBiotech). The plates were then washed and 
developed by adding substrate and determining absorbance at 405 nm.
For the peptide ELISAs, polystyrene plates were coated with 5 µg/ml 
streptavidin (100 µl/well) and kept overnight at 37°C. Then, plates were 
blocked with 2% BSA in PBS (200 µl/well) for 1 h at 37°C and washed with 
0.1% PBST. Subsequently, 5 µg/ml biotinylated peptides were added and 
incubated at room temperature for 1 h. After three washes with PBST, mAb 
MATERIALS AND METHODS
B. anthracis strains. B. anthracis Sterne strain 34F2 (pXO1 positive, pXO2 
negative) was obtained from A. Hoffmaster (Centers for Disease Control and 
Prevention, Atlanta, GA). Bacterial cultures were grown from frozen stocks 
in brain heart infusion broth (BD) at 37°C for 18 h (mid- to late-logarithmic 
phase) with shaking. Before experiments with the bacterial strain, the cells 
were washed. Recombinant PA and LF were obtained from Wadsworth 
Center (New York State Department of Health, Albany, NY).
Macrophages  and  hybridomas. Hybridoma cell lines were grown in 
DME (H-21; Invitrogen) supplemented with 10% (vol/vol) FCS, 5% Na-
tional Cancer Tissue Culture 109 (BioWhittaker), 1% nonessential amino 
acids (Invitrogen), and 1% penicillin. J774A.1 and RAW 264.7 macrophages 
(American Type Culture Collection) were maintained in DME and RPMI 
media, respectively, supplemented with 10% FCS and 1% penicillin (Media-
tech). Murine BMMs were isolated by flushing femoral and tibial bones of 
C57BL/6, FcR chain knockout (FcR/), and FcR chain/FcRII dou-
ble knockout (FcR//RIIB/) mice. Cells were differentiated into mac-
rophages (BMMs) by incubation for 6 d in DME supplemented with 1% 
penicillin, 100 µg/ml streptomycin, 10 mM Hepes, 2.0 mM L-glutamine, 
0.05 mM 2-mercaptoethanol, 1% mM of nonessential amino acids, 10% 
FCS, and 20% conditioned medium from a confluent culture of L929 fibro-
blasts as a source of CSF-1 (LCCM). After removal of nonadherent cells, 
macrophages were recovered by washing plates with cold PBS plus 5 mM 
EDTA.  BMMs  were  maintained  in  DME  supplemented  with  2  mM   
L-glutamine, 0.05 mM 2-mercaptoethanol, 1% nonessential amino acids,   
10 mM Hepes, 1% penicillin, 100 µg/ml streptomycin, 10% FCS, and 10% 
L929 preconditioned media.
Reagents. Caspase inhibitors BOC-D-FMK and BOC-D-CMK (EMD) 
were reconstituted in DMSO and used at a concentration of 40 µM. Rat 
anti–mouse CD16/CD32 mAb clone 2.4G2 (FcRII and FcRIII blocking 
mAb) was obtained from BD. mAb 9E9, which specifically blocks FcRIV, 
has been previously described (Kaneko et al., 2006). Cytochalasin d was ob-
tained from Sigma-Aldrich.
Ab purification. The 19D9 IgG1 was generated from mice immunized 
with a galactoxylomannan-PA conjugate made for other studies (De Jesus   
et al., 2009). For in vitro studies, antibodies were purified by protein G 
chromatography  (Thermo  Fisher  Scientific)  and  sterilized  by  filtering 
through a 0.2-mm-pore-size membrane (Sigma-Aldrich).
Isolation of isotype-switched variants. IgG2a and IgG2b isotype switch 
variants of mAb 19D9 were identified using the ELISA spot assay and iso-
lated by the sib selection technique. The assays were performed as previously 
reported with minor modifications (Greene et al., 1990; Spira and Scharff, 
1992). In brief, 103 cells were plated per well in a 96-well plate and grown 
for 3 d. Then, half of the cells were moved and subsequently examined for 
IgG2a or IgG2b switch variants using ELISA spot assay. The corresponding 
well with the highest number of spots was plated out in a new 96-well plate 
at progressively lower cell densities and duplicate plates were screened again 
for the frequency of switch variants. For the ELISA spot assay, 50 µl/well of 
the anti–mouse antibody against the corresponding isotype (SouthernBio-
tech) diluted 1:500 in coating buffer (20 mM K2HPO4, 10 mM KH2PO4,   
1 mM Na-EDTA, 0.8% NaCl, and 0.01% NaN3) was added to coat polysty-
rene plates and blocked with 2% BSA in TBS at 4°C. Plates were washed in 
TBS with 0.1% Tween 20 (TBS-T), rinsed with DME, and 4 × 103 cells 
were plated and incubated at 37°C for 16–18 h. The plates were washed 
with TBS-T, and 50 µl/well of biotinylated antibody against the corre-
sponding isotype (SouthernBiotech) diluted 1:500 in 2% BSA TBS was 
added for 2 h at 37°C, washed, and then treated with the Vectastain avidin 
phosphatase amplification system as per the manufacturer’s instructions (Vector 
Laboratories). The plates were washed and incubated with 1 mg/ml 5-bromo- 
4 chloro-3indoyl phosphate (Amresco) in AMP buffer (0.2 mg/mlCl2, 
0.01% Triton X-405, and 9.6% 2-amino-2-methyl-1-propanol, pH 9.8). JEM VOL. 207, October 25, 2010 
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6–8 wk of age. 10 mice per group were given 0.5 mg of IgG2a or isotype 
control antibody. mAb was administered via intraperitoneal injection 3 h   
before intravenous challenge with 104 B. anthracis Sterne, and mouse deaths 
were recorded daily. All experiments were done in compliance with federal 
laws and institutional guidelines and have been approved by the Albert Ein-
stein College of Medicine.
PA and IgG internalization assays. BMMs from wild-type and FcR//
RIIB/ mice were plated on MatTek plates, labeled with serum-free me-
dium containing 25 µg/ml Alex Fluor 488–conjugated IgG2a and Alexa 
Fluor 568–conjugated PA and incubated at 4°C for 2 h to enable binding. 
The  cells  were  washed,  warmed  to  37°C  for  varying  amounts  of  time, 
washed, and then fixed with 2% paraformaldehyde in PBS for 10 min at 
room temperature. The cells were subsequently imaged by epifluorescence 
microscopy on an inverted microscope (Axioskop 200; Carl Zeiss, Inc.) 
equipped with a cooled charge-coupled device using a 63× 1.4-NA objec-
tive with a 1.6× optovar. Images were acquired using the same exposure 
times and microscopic settings and processed by AxioVision software (ver-
sion 4.6; Carl Zeiss, Inc.).
Statistics. The statistical significance of differences in antibody LeTx neutral-
ization was determined using the Student’s t test and differences were consid-
ered significant at P < 0.01 (Prism software 5.0; GraphPad Software, Inc.). 
Survival rate was analyzed with Kaplan-Meier estimates, and the statistical sig-
nificance of differences in antibody B. anthracis Sterne toxin neutralization was 
determined using the log-rank test and P < 0.05 was considered significant. 
SPSS version 11.0 for Windows (SPSS Inc.) was used for statistical analysis.
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